The medical treatment of overactive bladder, including current and future treatments

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1041-1055

  Athanasopoulos, Anastasios ^a   Cruz, Francisco ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anticholinergics; antimuscarinics; beta 3 agonist; future treatments; medical treatment; overactive bladder; overactive detrusor; PDE5 inhibitors; pharmacotherapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANANDAMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPSAICIN; DARIFENACIN; DESMOPRESSIN; ENDOVANILLOID; FESOTERODINE; ICOSANOID; IMIPRAMINE; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; N ARACHIDONOYLDOPAMINE; N OLEOYLDOPAMINE; OXYBUTYNIN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; PROPIVERINE; PURINERGIC RECEPTOR BLOCKING AGENT; RESINIFERATOXIN; SILDENAFIL; SOLABEGRON; SOLIFENACIN; TACHYKININ RECEPTOR ANTAGONIST; TADALAFIL; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR AGONIST; VARDENAFIL;

APPLICATION SITE REACTION; ATTENTION; BACKACHE; BLADDER CAPACITY; BLADDER TRAINING; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPONATREMIA; LOWER URINARY TRACT SYMPTOM; MEMORY; NOCTURIA; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SATISFACTION; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; XEROSTOMIA;

FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 79953837756     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.554399     Document Type: Review

References (157)

1. Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2010: doi:10.1016/j.eururo.2010.11.040
2. Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 2009;12:259-69
3. Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010;29:112-15
4. Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol 2001;19(5):312-18 (Pubitemid 33777076)
5. Robinson D, Cardozo L. The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin Investig Drugs 2004;13(10):1339-48 (Pubitemid 39359663)
6. Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colon R. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clin Ther 2006;28:1247-72 (Pubitemid 44585291)
7. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 2004;13(11):1493-500 (Pubitemid 39530201)
8. Haab F. Darifenacin for the treatment of overactive bladder. Womens Health 2005;1:331-43
9. Hofner K, Oelke M, Machtens S, Grunewald V. Trospium chloride-an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001;19(5):336-43 (Pubitemid 33777079)
10. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46 (Pubitemid 39472630)
11. Michel MC. Fesoterodine, a novel muscarinic receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother 2008;9:1787-96
12. Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001;19(5):319-23 (Pubitemid 33777077)
13. De Wachter S, Wyndaele JJ. Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 2003;169(5):1892-5 (Pubitemid 36443540)
14. Davila GW. Transdermal oxybutynin: a new treatment for overactive bladder. Expert Opin Pharmacother 2003;4:2315-24 (Pubitemid 37541244)
15. Siddiqui MAA, Perry CM, Scott LJ. Oxybutynin extended-release. A review of its use in the management of overactive bladder. Drugs 2004;64:885-912 (Pubitemid 38580895)
16. Madersbacher H, Murtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001;19(5):324-35 (Pubitemid 33777078)
17. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54(3):543-62
18. Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64
19. Witte LPW, Mulder WMC, de la Rosette JJMCH, Michel MC. Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 2009;19:13-19
20. Anderson KE, Yoshida M. Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 2003;43:1-5 (Pubitemid 36134308)
21. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3(1):46-53
22. Chapple CR, Fianu-Jonsson A, Indig M, et al. STAR study group: treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007;52(4):1195-203 (Pubitemid 47337035)
23. Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 2005;59(8):931-7
24. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
25. Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother 2005;6(14):2429-33 (Pubitemid 41701045)
26. Athanasopoulos A. Antimuscarinics and bladder outlet obstruction: from a contraindication to an indication? Neurourol Urodyn 2010;29(Suppl 1):S46-50
27. Athanasopoulos A, Mitropoulos D, Giannitsas K, Perimenis P. Safety of anticholinergics in patients with benign prostatic hyperplasia. Expert Opin Drug Saf 2008;7(4):473-9
28. Chapple C Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol 2010;20; 1: 43-8.
29. Fullhase C, Soler R, Gratzke C, et al. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int 2010;106(2):287-93
30. Conte-Santos G, Rebbassa-Llull M, Soriano-Burrull L, et al. Study of safety and urodynamic characteriztion of treatment with tamsulosin, tolderodine and tamsulosin plus tolderodine, in men with LUTS [abstract 468]. Eur Urol Suppl 2009;8(4):237
31. Blake-James T, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2006;99:85-96
32. Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006;50:675-83 (Pubitemid 44332687)
33. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 2003;326(7394):841-4 (Pubitemid 36461413)
34. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48(1):5-26 (Pubitemid 40835585)
35. Kirby M, Artibani W, Cardozo L, et al. Overactive bladder: the importance of new guidance. Int J Clin Pract 2006;60(10):1263-71 (Pubitemid 44363664)
36. Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009;10(18):3103-11
37. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial. Mayo Clin Proc 2003;78:687-95 (Pubitemid 36665898)
38. Appell RA, Sand P, Dmochowski R, et al. Overactive bladder: judging effective control and treatment study group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76(4):358-63 (Pubitemid 32248750)
39. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007;99(4):836-44 (Pubitemid 46439555)
40. Pizzi LT, Talati A, Gemmen E, et al. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics 2009;27(4):329-39
41. Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Investig 2004;24(6):305-21 (Pubitemid 38858254)
42. Hanawa T, Tsuchiya C, Endo N, et al. Formulation study of intravesical oxybutynin instillation solution with enhanced retention in bladder. Chem Pharm Bull (Tokyo) 2008;56(8):1073-6
43. Peeker R, Samsioe G, Kowalski J, et al. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden. Scand J Urol Nephrol 2010;44(3):138-46
44. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81(6):801-10 (Pubitemid 28300606)
45. Giannitsas K, Perimenis P, Athanasopoulos A, et al. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 2004;46(6):776-82 (Pubitemid 39488412)
46. Madersbacher H, Halaska M, Voigt R, et al. Placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Br J Urol Int 1999;84(6):646-51 (Pubitemid 29457181)
47. Junemann KP, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 2005;48(3):478-82 (Pubitemid 41188408)
48. Madersbacher H, Murtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001;19(5):324-35 (Pubitemid 33777078)
49. Alloussi SH, Murtz G, Seibold J, et al. Antimuscarincs in children: is its use in children evidence-based? [abstract 292]. Int Urogynecol J 2010;21(Suppl 1):428
50. Lee KS, Lee HW, Choo MS, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU Int 2009. [Epub ahead of print]
51. Siegmund W, Sillen U, Lackgren G, et al. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder. Clin Pharmacokinet 2010;49(5):335-42
52. Dwyer P, Kelleher C, Young J, et al. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn 2008;27(6):540-7
53. Zinner N, Kobashi KC, Ebinger U, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 2008;62(11):1664-74
54. Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 2005; 48:(3) 483-7. (Pubitemid 41188409)
55. Chapple CR, Martinez-Garcia R, Selvaggi L, et al.; for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48(3):464-70 (Pubitemid 41188406)
56. Cardozo L, Hessdorfer E, Milani R, et al.; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102(9):1120-7
57. Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73(1):14-18
58. Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81
59. Swift SE, Siami P, Forero-Schwanhaeuser S. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: an open-label, flexible-dosing, multicentre study. Clin Drug Investig 2009;29(5):305-16
60. Wong C, Duggan P. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. J Obstet Gynaecol 2009;29(1):31-4
61. Milsom I, Axelsen S, Kulseng-Hansen S, et al. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand 2009;88(6):693-9
62. Vardy MD, Mitcheson HD, Samuels TA, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial. Int J Clin Pract 2009;63(12):1702-14
63. Zinner N, Gittelman M, Harris R, Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171(6):2311-15 (Pubitemid 38625460)
64. Cardozo L, Mirone V, Gratzke C, Marberger M. Extended-release Trospium chloride 60 mg-a new once-daily medication for the treatment of overactive bladder syndrome. Eur Urol Rev 2010;5(1):3-6
65. Nitti V, Wiatrak M, Kreitman L, Lipsitz D. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB)Q results of a phase 2 trial. Paper presented at International Continence Society; Montreal, Canada; August 31-September 2 2005
66. Chaple C, Kerrebrock PV, Tubaro A. Clinical efficacy, safety, and tolerability of once-daily fesotrodine in subjects with overactive bladder. Eur Urol 2007;52(4):1204-12 (Pubitemid 47332062)
67. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2010. [Epub ahead of print]
68. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolderodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010;105(1):58-66
69. Wyndaele J-J, Goldfischer ER, Morrow JD, et al. Effects of flexiple-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label stydy. Int J Clin Pract 2009;63(4):560-7
70. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 1999;161(5):1551-5 (Pubitemid 29420817)
71. Yarker YE, Goa KL, Fitton A, et al. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6(3):243-62
72. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62(11):1792-800
73. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50(2):317-26 (Pubitemid 44038078)
74. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173(2):493-8
75. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008;62(11):1792-800
76. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 2010;58(8):1618-19
77. Malhotra B, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009;16(33):4481-9
78. Alloussi S, Murtz G, Braun R, et al. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: results of a multicentre observational cohort study. BJU Int 2010;106(4):550-6
79. Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther 2008;13(4):241-51
80. Serra DB, Affrime MB, Bedigian MP, et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45(9):1038-47 (Pubitemid 41192363)
81. Hussain RM, Hartigan-Go K, Thomas SH, Ford A. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996;41(1):73-5 (Pubitemid 26011405)
82. Malhotra BK, Glue P, Sweeney K, et al. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 2007;81(3):377-85 (Pubitemid 46364489)
83. Homma Y, Yamaguchi O, Imidafenacin Study Group. A randomized, double-blind, placebo-and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16(5):499-506
84. Malhotra B, Wood N, Sachse R, Gandelman K Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 2010;48(5):309-18
85. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006;98(5):1025-32 (Pubitemid 44536453)
86. Michel MC, Wetterauer U, Vogel M, de la Rosette JJ. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug Saf2008;31(6):505-14 (Pubitemid 351693683)
87. Junemann KP, Al-Shukri S. Efficacy and tolerability of trospium chloride and tolderodine in 234 patients with urge-syndrome: a double blind, placebo controlled multicenter clinical trial. Neurourl Urodyn 2000;19:488-93
88. Sand P, Morrow J, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J 2009;20:827-35
89. Chapple CR, Rosenberg MT, Brenes FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009;104(7):960-7
90. Wong C, Duggan P. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study. J Obstet Gynaecol. 2009;29(1):31-4
91. Chancellor MB, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008;30(10):1766-81
92. Zinner N, Kobashi KC, Ebinger U, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 2008;62(11):1664-74
93. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. BJU Int 2010. [Epub ahead of print]
94. Sears CL, Lewis C, Noel K, et al. Overactive bladder medication adherence when medication is free to patients. J Urol 2010;183(3):1077-81
95. D'souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14(3):291-301 (Pubitemid 351711980)
96. Hunsballe JM, Djurhuus JC Clinical options for imipramine in the management of urinary incontinence. Urol Res 2001;29(2):118-25 (Pubitemid 32422513)
97. Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002;89(9):855-62 (Pubitemid 34535416)
98. Lose G, Lalos O, Freeman RM, et al.; Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003;189(4):1106-13 (Pubitemid 37373906)
99. Robinson D, Cardozo L, Akeson M, et al. Antidiuresis: a new concept in managing female daytime urinary incontinence BJU Int 2004;93(7):996-1000 (Pubitemid 38758621)
100. Levin RM, Ruggieri MR, Wein AJ. Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. J Urol 1988;139(4):844-8
101. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;84(3):935-86 (Pubitemid 38823771)
102. Michel MC, Vrydag W. Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88-119
103. Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377(4-6):473-81
104. Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (BLOSSOM) shows novel beta3 adrenoreceptor agoinist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;3:239
105. Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily Mirabegron (YM178), a novel selective beta3-adrenoreceptor agonist, with overactive bladder (OAB). Eur Urol Suppl 2010;2:249
106. Gomelsky A, Dmochowski RR Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr Urol Rep 2010; 11(4) 254-60.
107. Behr-Roussel D, Oger S, Caisey S, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol 2010. [Epub ahead of print]
108. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90(9):836-9 (Pubitemid 36693615)
109. McVary KT, Monnig W, Camps JL Jr, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177(3):1071-7 (Pubitemid 46216352)
110. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177(4):1401-7 (Pubitemid 46435965)
111. Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53(6):1236-44
112. Dmochowski R, Roehrborn C, Klise S, et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2010;183(3):1092-7
113. Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006;373(4):287-99 (Pubitemid 43999780)
114. Charrua A, Cruz CD, Cruz F, Avelino A. Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J Urol 2007;177(4):1537-41 (Pubitemid 46436017)
115. Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002;168(2):575-9 (Pubitemid 34793300)
116. Kuo HC, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol 2006;176(2):641-5
117. Silva C, Silva J, Castro H, et al. Bladder sensory desensitization decreases urinary urgency. BMC Urol 2007;7:9
118. Charrua A, Cruz CD, Narayanan S, et al. GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 2009;181(1):379-86
119. Silva A, Cruz CD, Charrua A, et al. GRC 6211, a new oral TRPV1 antagonist, decreases neurogenic detrusor overactivity in a rat model of spinal cord transection. Neurourol Urodyn 2008;27(7):597-8
120. Szallasi A, Cruz F, Geppetti P. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 2006;12(11):545-54 (Pubitemid 44633805)
121. Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med 2009;15:14-22
122. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400:452-7 (Pubitemid 29361798)
123. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002;99:8400-5 (Pubitemid 34651064)
124. Chu CJ, Huang SM, De Petrocellis L, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 2003;278:13633-9 (Pubitemid 36799898)
125. Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000;97:6155-60 (Pubitemid 30367539)
126. Shin J, Cho H, Hwang SW, et al. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci USA 2002;99:10150-5 (Pubitemid 34831187)
127. Dinis P, Charrua A, Avelino A, et al. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 2004;24:11253-63 (Pubitemid 39658260)
128. Stein EA, Fuller SA, Edgemond WS, Campbell WB. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol 1996;119:107-14 (Pubitemid 26294529)
129. Tyagi V, Philips BJ, Su R, et al. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 2009;181(4):1932-8
130. Lecci A, Maggi CA. Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept 2001;101(1-3):1-18 (Pubitemid 32728365)
131. Ishizuka O, Mattiasson A, Andersson KE. Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats. J Urol 1995;154(4):1548-51
132. Smet PJ, Moore KH, Jonavicius J. Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 1997;77(1):37-49 (Pubitemid 27328358)
133. Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176(6 Pt 1):2535-40 (Pubitemid 44665982)
134. Frenkl TL, Zhu H, Reiss T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010;184(2):616-22
135. Gopalakrishnan M, Shieh CC. Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Expert Opin Ther Targets 2004;8(5):437-58 (Pubitemid 39359650)
136. Connolly MJ, Astridge PS, White EG, et al. Torsades de pointes ventricular tachycardia and terodiline. Lancet 1991;338(8763):344-5
137. Howe BB, Halterman TJ, Yochim CL, et al. Zeneca ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder. J Pharmacol Exp Ther 1995;274:884-90
138. Shieh CC, Turner SC, Zhang XF, et al. A-272651, a nonpeptidic blocker of large-conductance Ca2+-activated K+ channels, modulates bladder smooth muscle contractility and neuronal action potentials. Br J Pharmacol 2007;151(6):798-806 (Pubitemid 47075318)
139. Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol 2006;49:879-86
140. Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour inP2X3-deficient mice. Nature 2000;407:1011-15
141. Vlaskovska M, Kasakov L, Rong W, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci 2001;21:5670-7 (Pubitemid 32692165)
142. O'Reilly BA, Kosaka AH, Knight GF, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002;167:157-64 (Pubitemid 34024522)
143. Kim JC, Park EY, Seo SI, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006;175(5):1773-6
144. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009;56(4):700-6
145. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010;58(3):360-5
146. Qiao LY, Vizzard MA. Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J Comp Neurol 2002;454(2):200-11 (Pubitemid 35265964)
147. Qiao LY, Vizzard MA. Spinal cord injury-induced expression of TrkA, TrkB, phosphorylated CREB, and c-Jun in rat lumbosacral dorsal root ganglia. J Comp Neurol 2005;482(2):142-54 (Pubitemid 40066645)
148. Seki S, Sasaki K, Igawa Y, et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol 2004;171(1):478-82 (Pubitemid 37549215)
149. Pinto R, Frias B, Allen S, et al. Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 2010;166(3):907-16
150. Cardozo LD, Stanton SL, Robinson H, Hole D. Evaluation on flurbiprofen in detrusor instability. Br Med J 1980;280:281
151. Palmer J. Report of a double-blind crossover study of flurbiprofen and placebo in detrusor instability. J Int Med Res 1983;(11 Suppl 2):11
152. Cardozo LD, Stanton SL. A comparison between bromocriptine and indomethacin in the treatment of detrusor instability. J Urol 1980;123:399
153. Wilbraham D, Masuda T, Deacon S, et al. Safety, tolerability, and pharmacokinetic of multiple ascending doses Of the EP-1 receptor antagonist ONO-8539, a potential new and novel therapy to overactive bladder in healthy young and elderly subjects. Eur Urol Suppl 2010;2:250
154. Rajasekaran M, Wilkes N, Kuntz S, Albo EM. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. Neurourol Urodyn 2005;24(3):295-300 (Pubitemid 40617107)
155. Broqueres-You D, Behr-Roussel D, Oger S, et al. Rho-kinase inhibition impacts neurogenic detrusor overactivity in chronic spinalized rats. Eur Urol Suppl 2010;2:112
156. Cruz CD, Avelino A, McMahon SB, Cruz F. Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. Eur J Neurosci 2005;21(3):773-81 (Pubitemid 40363511)
157. Cruz CD, McMahon SB, Cruz F. Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Exp Neurol 2006;200(1):66-73 (Pubitemid 44080747)